JW Pharmaceutical develops dutasteride tablet for treatment of hair loss and benign prostatic hyperplasia
Developing dutasteride as tablets, JW Pharmaceutical is going to target the world’s KRW 1 trillion market.
JW Pharmaceutical announced on the 12th the company succeeded in developing ‘dutasteride,’ a hair loss and benign prostatic hyperplasia treatment which originally was a soft capsule, as a t...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.